The Fort Worth Press - Avant Technologies and Partner, Ainnova, Finalizing Automated Retinal Camera Prototype Ahead of Full-Scale Development

USD -
AED 3.672504
AFN 65.000368
ALL 81.910403
AMD 376.168126
ANG 1.79008
AOA 917.000367
ARS 1431.790402
AUD 1.425923
AWG 1.8025
AZN 1.70397
BAM 1.654023
BBD 2.008288
BDT 121.941731
BGN 1.67937
BHD 0.375999
BIF 2954.881813
BMD 1
BND 1.269737
BOB 6.889932
BRL 5.217404
BSD 0.997082
BTN 90.316715
BWP 13.200558
BYN 2.864561
BYR 19600
BZD 2.005328
CAD 1.36855
CDF 2200.000362
CHF 0.77566
CLF 0.021803
CLP 860.890396
CNY 6.93895
CNH 6.929815
COP 3684.65
CRC 494.312656
CUC 1
CUP 26.5
CVE 93.82504
CZK 20.504104
DJF 177.555076
DKK 6.322204
DOP 62.928665
DZD 129.553047
EGP 46.73094
ERN 15
ETB 155.0074
EUR 0.846204
FJD 2.209504
FKP 0.735067
GBP 0.734457
GEL 2.69504
GGP 0.735067
GHS 10.957757
GIP 0.735067
GMD 73.000355
GNF 8752.167111
GTQ 7.647681
GYD 208.609244
HKD 7.81385
HNL 26.45504
HRK 6.376104
HTG 130.618631
HUF 319.703831
IDR 16855.5
ILS 3.110675
IMP 0.735067
INR 90.57645
IQD 1310.5
IRR 42125.000158
ISK 122.710386
JEP 0.735067
JMD 156.057339
JOD 0.70904
JPY 157.200504
KES 128.622775
KGS 87.450384
KHR 4033.00035
KMF 419.00035
KPW 900.021111
KRW 1463.803789
KWD 0.30721
KYD 0.830902
KZT 493.331642
LAK 21426.698803
LBP 89293.839063
LKR 308.47816
LRD 187.449786
LSL 16.086092
LTL 2.95274
LVL 0.60489
LYD 6.314009
MAD 9.185039
MDL 17.000296
MGA 4426.402808
MKD 52.129054
MMK 2100.115486
MNT 3570.277081
MOP 8.023933
MRU 39.850379
MUR 46.060378
MVR 15.450378
MWK 1737.000345
MXN 17.263604
MYR 3.947504
MZN 63.750377
NAD 16.086092
NGN 1366.980377
NIO 36.694998
NOK 9.690604
NPR 144.506744
NZD 1.661958
OMR 0.383441
PAB 0.997082
PEN 3.367504
PGK 4.275868
PHP 58.511038
PKR 278.812127
PLN 3.56949
PYG 6588.016407
QAR 3.64135
RON 4.310404
RSD 99.553038
RUB 76.792845
RWF 1455.283522
SAR 3.749738
SBD 8.058149
SCR 13.675619
SDG 601.503676
SEK 9.023204
SGD 1.272904
SHP 0.750259
SLE 24.450371
SLL 20969.499267
SOS 568.818978
SRD 37.818038
STD 20697.981008
STN 20.719692
SVC 8.724259
SYP 11059.574895
SZL 16.08271
THB 31.535038
TJS 9.342721
TMT 3.505
TND 2.847504
TOP 2.40776
TRY 43.612504
TTD 6.752083
TWD 31.590367
TZS 2577.445135
UAH 42.828111
UGX 3547.71872
UYU 38.538627
UZS 12244.069517
VES 377.985125
VND 25950
VUV 119.620171
WST 2.730723
XAF 554.743964
XAG 0.012866
XAU 0.000202
XCD 2.70255
XCG 1.797032
XDR 0.689923
XOF 554.743964
XPF 101.703591
YER 238.403589
ZAR 16.04457
ZMK 9001.203584
ZMW 18.570764
ZWL 321.999592
  • SCS

    0.0200

    16.14

    +0.12%

  • CMSD

    0.0600

    23.95

    +0.25%

  • RBGPF

    0.1000

    82.5

    +0.12%

  • NGG

    1.1700

    88.06

    +1.33%

  • BCE

    -0.4900

    25.08

    -1.95%

  • CMSC

    -0.0400

    23.51

    -0.17%

  • BCC

    1.8700

    91.03

    +2.05%

  • RIO

    2.2900

    93.41

    +2.45%

  • RELX

    -0.7100

    29.38

    -2.42%

  • RYCEF

    0.2600

    16.88

    +1.54%

  • GSK

    1.0600

    60.23

    +1.76%

  • JRI

    0.0900

    12.97

    +0.69%

  • VOD

    0.4900

    15.11

    +3.24%

  • BTI

    0.8400

    62.8

    +1.34%

  • BP

    0.8400

    39.01

    +2.15%

  • AZN

    5.8700

    193.03

    +3.04%

Avant Technologies and Partner, Ainnova, Finalizing Automated Retinal Camera  Prototype Ahead of Full-Scale Development
Avant Technologies and Partner, Ainnova, Finalizing Automated Retinal Camera Prototype Ahead of Full-Scale Development

Avant Technologies and Partner, Ainnova, Finalizing Automated Retinal Camera Prototype Ahead of Full-Scale Development

LAS VEGAS, NEVADA / ACCESS Newswire / June 10, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced the Company is in the final stages of prototyping its proprietary automated retinal camera. Ainnova's new device will offer users a low cost, easier to use camera that captures images automatically and then uploads those images to the Company's Vision AI software platform, which then produces a "risk report" in mere seconds.

Text size:

Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said, "The cost of a fundus camera has always been a barrier to entry into in this market, so our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market.

"Another significant advantage will be that our camera will be seamlessly packaged together with our Vision AI platform, allowing us to refer more patients in less time and accurately to medical specialists. Also, one of our objectives is to integrate other technologies to this preventive screening, expanding the scope from only diabetic patients to patients who have other risk factors and want to prevent other diseases from a more complete approach."

Vision AI is a powerful cutting-edge, AI-driven platform that can quickly and accurately detect the early markers of a host of diseases by applying AI models to examine imaging data from the eye to expedite earlier detection and allow patients to better manage their disease. The diseases that Vision AI can detect, include diabetic retinopathy, other retinopathies, such as glaucoma, macular edema, age-related macular degeneration, and other anomalies, as well as other diseases that do not require retinal images, and instead, use other datapoints that Ainnova has integrated into the software like the detection of cardiovascular disease (CVD), type 2 diabetes, liver fibrosis, and chronic kidney disease (CKD).

Currently, Ainnova's Vision AI software works well with any fundus camera on the market; however, Ainnova and Avant are aiming for exclusivity by developing a lower-cost, easier to use camera.

Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova, will develop the retinal cameras as part of the joint venture and licensing deal to facilitate the development of Ainnova's technology portfolio. AAC owns the global licensing rights to develop, maintain, and market Ainnova's technology portfolio.

About Ainnova Tech, Inc.

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI - our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

About Avant Technologies Inc.

Avant Technologies Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

More information about Avant can be found at https://avanttechnologies.com

You can also follow us on social media at:

https://twitter.com/AvantTechAI

https://www.linkedin.com/company/avant-solutionspr/

https://www.facebook.com/AvantTechAI

https://www.youtube.com/@AvantTechAI

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.

Contact:

Avant Technologies Inc.
[email protected]

SOURCE: Avant Solutions



View the original press release on ACCESS Newswire

W.Matthews--TFWP